About the Company
ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ. In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure. ChromaDex no longer sells pTeroPure.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CDXC News
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ...
ChromaDex (CDXC) Price Target Increased by 9.92% to 6.60
The average one-year price target for ChromaDex (NasdaqCM:CDXC) has been revised to 6.60 / share. This is an increase of 9.92 ...
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one ...
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third ...
ChromaDex Stock (NASDAQ:CDXC), Analyst Ratings, Price Targets, Predictions
$3.58 207.26% HC Wainwright & Co.
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
ChromaDex Corporation is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine ...
ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript March 6, 2024 ChromaDex Corporation beats earnings expectations. Reported EPS is $0.00152, expectations were $-0.03. ChromaDex ...
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex ...
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one ...
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results. “ChromaDex had its strongest year yet, achieving $83.6 million in revenue, up 16% year-over ...
Loading the latest forecasts...